SCYNEXIS To Present Preclinical Data On Second Generation Fungerp SCY-247 At The 11th Congress On Trends In Medical Mycology October 20-23 In Athens, Greece
Portfolio Pulse from Benzinga Newsdesk
SCYNEXIS, Inc. (NASDAQ:SCYX) announced the presentation of preclinical data on its second generation antifungal compound, SCY-247, at the 11th Congress on Trends in Medical Mycology. SCY-247 has demonstrated broad-spectrum antifungal activity and SCYNEXIS anticipates that the FDA may grant it Qualified Infectious Disease Product and Fast Track designations. Clinical studies are planned to begin in the second half of 2024.
October 16, 2023 | 12:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
SCYNEXIS's announcement of preclinical data on SCY-247 and potential FDA designations could positively impact investor sentiment.
The announcement of positive preclinical data on SCY-247 and potential FDA designations could increase investor confidence in SCYNEXIS's pipeline and future prospects, potentially leading to a short-term increase in the company's stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100